MannKind (NASDAQ:MNKD) PT Raised to $7.50

MannKind (NASDAQ:MNKD – Get Free Report) had its price target upped by investment analysts at Cantor Fitzgerald from $6.50 to $7.50 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 41.78% from […]

Related Keywords

Michael Castagna ,Alfrede Mann ,Stevenb Binder ,Cantor Fitzgerald ,Securities Exchange Commission ,Cetera Advisor Networks ,Topco Ltd ,Mannkind Company Profile ,First Horizon Advisors Inc ,Mannkind Corp ,Cetera Advisors ,International Assets Investment Management ,Get Free Report ,Kind Stock Down ,Exchange Commission ,Assets Investment Management ,Horizon Advisors ,Mannkind Daily ,Mannkind ,Nasdaq Mnkd ,Mnkd ,Medical ,56400p20 ,Boost Price Target ,